Results 11 to 20 of about 475,313 (268)
Perioperative optimization of Crohn's disease
Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 10-26, January 2023., 2023 Most Crohn's disease patients require surgery during the course of their illness, especially those who experience complications. The management of perioperative medications and surgery‐related decision‐making should be individualized and patient‐centered based on a multidisciplinary approach.
Chun‐Chi Lin +10 more
wiley +1 more source
COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2
Brain and Behavior, Volume 12, Issue 12, December 2022., 2022 Abstract Introduction This review highlights the potential mechanisms of neuromuscular manifestation of COVID‐19, especially myasthenia gravis (MG). Methods An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020. Results Exacerbations of clinical symptoms
Syed Muhammad Ismail Shah +10 more
wiley +1 more source
Clinical Cardiology, Volume 45, Issue 12, Page 1255-1263, December 2022., 2022 Abstract Background The definitive treatment for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA), which has good long‐term outcomes. However, after surgery, a quarter of the patients still have residual pulmonary hypertension (RPH). In pulmonary hemodynamics, there are no unified criteria for RPH, even though the
Wu Song +4 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 423-434, February 2023., 2023 This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding.
Tjeerd Pieter van Staa +4 more
wiley +1 more source
Journal of Thrombosis and Haemostasis, 2020 The novel coronavirus disease of 2019 (COVID-19) pandemic, as declared by the World Health Organization, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Cardiovascular disease and, in particular, venous thromboembolism (VTE)
A. Spyropoulos +10 more
semanticscholar +1 more source
Milvexian for the Prevention of Venous Thromboembolism.
New England Journal of Medicine, 2021 BACKGROUND Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants.
J. Weitz +10 more
semanticscholar +1 more source
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Research and Practice in Thrombosis and Haemostasis, 2020 Venous thromboembolism (VTE) is frequently observed in patients with coronavirus disease 2019 (COVID‐19). However, reported VTE rates differ substantially.
S. Nopp +4 more
semanticscholar +1 more source
A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension [PDF]
, 2021 Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by recurrent or unresolved pulmonary thromboemboli, leading to perfusion defects and increased arterial wave reflections. CTEPH treatment aims to reduce pulmonary arterial pressure and reestablish adequate lung perfusion, yet patients with distal lesions are inoperable by standard surgical
arxiv +1 more source
Venous thromboembolism in cancer patients: a population-based cohort study.
Blood, 2020 The incidence of venous thromboembolism in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved survival, and high-resolution imaging.
F. Mulder +8 more
semanticscholar +1 more source